Literature DB >> 25217433

Polypharmacy in heart failure: drugs to use and avoid.

Brent N Reed1, Jo E Rodgers2, Carla A Sueta3.   

Abstract

Polypharmacy, the use of 4 or more medications, is universal in patients with heart failure (HF). Evidence-based combination therapy is prescribed in patients with HF with reduced ejection fraction (HFrEF). Additionally, treatment of the high prevalence of comorbidities presents many therapeutic dilemmas. The use of nonprescription medications is common, adding further complexity to the medication therapy regimens of patients with HF. An approach for combining evidence-based therapies in patients with HFrEF is presented. Strategies for optimizing the management of common comorbidities in patients with HF are reviewed. Both prescription and nonprescription medications to avoid or use with caution are highlighted.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Comorbidities; Heart failure; Polypharmacy

Mesh:

Substances:

Year:  2014        PMID: 25217433     DOI: 10.1016/j.hfc.2014.07.005

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  4 in total

Review 1.  Heart Failure in Older Adults.

Authors:  Hoda Butrous; Scott L Hummel
Journal:  Can J Cardiol       Date:  2016-05-10       Impact factor: 5.223

Review 2.  Systematizing Heart Failure Population Health.

Authors:  Prateeti Khazanie; Larry A Allen
Journal:  Heart Fail Clin       Date:  2020-07-21       Impact factor: 3.179

3.  Potentially inappropriate medications for patients with heart failure and risk of hospitalization from heart failure: A case-control study from Thailand.

Authors:  Kittipak Jenghua; Surarong Chinwong; Dujrudee Chinwong; Panadda Ngamsom; Roungtiva Muenpa; Penkarn Kanjanarat
Journal:  Pharm Pract (Granada)       Date:  2022-01-06

4.  Statins are associated with reduced likelihood of sarcopenia in a sample of heart failure outpatients: a cross-sectional study.

Authors:  Rui Valdiviesso; Ana Rita Sousa-Santos; Luís F Azevedo; Emília Moreira; Teresa F Amaral; José Silva-Cardoso; Nuno Borges
Journal:  BMC Cardiovasc Disord       Date:  2022-08-05       Impact factor: 2.174

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.